DDInter1042 DDInter813
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth.
Gemifloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Gemifloxacin {u} (Compound) resembles {v} (Compound) Levofloxacin
Gemifloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Gemifloxacin {u} (Compound) causes {v} (Side Effect) Tendon rupture
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Gemifloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Procarbazine
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Gemifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Terfenadine
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Gemifloxacin {u} may lead to a major life threatening interaction when taken with {v} Triamcinolone
Gemifloxacin (Compound) resembles Lomefloxacin (Compound)
Gemifloxacin (Compound) resembles Levofloxacin (Compound)
Gemifloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Gemifloxacin (Compound) causes Tendon rupture (Side Effect)
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan
Gemifloxacin may cause a minor interaction that can limit clinical effects when taken with Procarbazine
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Gemifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine
Gemifloxacin may lead to a major life threatening interaction when taken with Nilotinib
Gemifloxacin may lead to a major life threatening interaction when taken with Triamcinolone